Publications

Analytical biochemistry

32P-postlabeling assay for the quantification of the major platinum-DNA adducts.

01-11-1999

Clinical cancer research : an official journal of the American Association for Cancer Research

Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.

01-11-1999

Anti-cancer drugs

Compatibility and stability of aplidine, a novel marine-derived depsipeptide antitumor agent, in infusion devices, and its hemolytic and precipitation potential upon i.v. administration.

01-11-1999

Clinical cancer research : an official journal of the American Association for Cancer Research

Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice.

01-10-1999

Proceedings of the National Academy of Sciences of the United States of America

Mice without phosphatidylcholine transfer protein have no defects in the secretion of phosphatidylcholine into bile or into lung airspaces.

28-09-1999

Nederlands tijdschrift voor geneeskunde

[Hyperthermic intra-peritoneal chemotherapy (HIPEC) in patients with peritoneal pseudomyxoma or peritoneal metastases of colorectal carcinoma; good preliminary results from the Netherlands Cancer Institute].

11-09-1999

British journal of cancer

Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients.

01-09-1999

Cancer chemotherapy and pharmacology

Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours.

14-08-1999

European journal of drug metabolism and pharmacokinetics

Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC).

21-07-1999

Pharmacological research

Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion.

01-07-1999

British journal of cancer

Oral topotecan: bioavailablity and effect of food co-administration.

01-07-1999

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors.

01-06-1999

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.

01-06-1999

Cancer chemotherapy and pharmacology

Paclitaxel in the treatment of human immunodeficiency virus 1-associated Kaposi's sarcoma--drug-drug interactions with protease inhibitors and a nonnucleoside reverse transcriptase inhibitor: a case report study.

13-05-1999

Journal of chromatography. B, Biomedical sciences and applications

Quantification of topotecan and its metabolite N-desmethyltopotecan in human plasma, urine and faeces by high-performance liquid chromatographic methods.

30-04-1999

Cancer treatment reviews

Clinical pharmacology of anticancer agents in relation to formulations and administration routes.

01-04-1999

The Journal of pharmacology and experimental therapeutics

Comparative pharmacokinetics of vinblastine after a 96-hour continuous infusion in wild-type mice and mice lacking mdr1a P-glycoprotein.

01-04-1999

Cancer chemotherapy and pharmacology

A single 24-hour plasma sample does not predict the carboplatin AUC from carboplatin-paclitaxel combinations or from a high-dose carboplatin-thiotepa-cyclophosphamide regimen.

01-04-1999

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.

01-03-1999

British journal of cancer

Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer.

01-03-1999

British journal of cancer

Potentiation of anti-cancer drug activity at low intratumoral pH induced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG).

01-02-1999

Therapeutic drug monitoring

Sampling technique from central venous catheters proves critical for pharmacokinetic studies.

01-02-1999

British journal of cancer

Bioavailability and toxicity after oral administration of m-iodobenzylguanidine (MIBG).

01-02-1999

Anti-cancer drugs

Topoisomerase I/II inhibitor intoplicine administered as a 24 h infusion: phase I and pharmacologic study.

01-01-1999

British journal of cancer

Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein.

01-01-1999

Investigational new drugs

Pharmaceutical development of a parenteral lyophilized formulation of the investigational antitumor neuropeptide antagonist [Arg6, D-Trp7,9, MePhe8]-Substance P [6-11].

16-12-1998

Journal of chromatography. B, Biomedical sciences and applications

High-performance liquid chromatographic bio-analysis of PSC 833 in human and murine plasma.

20-11-1998

Journal of mass spectrometry : JMS

Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

01-11-1998

The Annals of pharmacotherapy

Hepatitis during chloroguanide prophylaxis.

01-10-1998

Cancer treatment reviews

In-vitro metabolism of anti-cancer drugs, methods and applications: paclitaxel, docetaxel, tamoxifen and ifosfamide.

01-10-1998

Clinical cancer research : an official journal of the American Association for Cancer Research

Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A.

01-10-1998

Journal of chromatography. B, Biomedical sciences and applications

High-performance liquid chromatographic determination of stabilized 4-hydroxyifosfamide in human plasma and erythrocytes.

25-09-1998

Journal of chromatography. B, Biomedical sciences and applications

Simultaneous determination of N,N',N"-triethylenethiophosphoramide, cyclophosphamide and some of their metabolites in plasma using capillary gas chromatography.

25-09-1998

The Journal of experimental medicine

Multidrug resistance protein 1 protects the oropharyngeal mucosal layer and the testicular tubules against drug-induced damage.

07-09-1998

Anti-cancer drugs

Phase I and pharmacologic study of weekly doxorubicin and 1 h infusional paclitaxel in patients with advanced breast cancer.

01-09-1998

Pharmacological research

Pharmacologic study of 3-hour 135 mg M-2 paclitaxel in platinum pretreated patients with advanced ovarian cancer.

01-09-1998

Journal of pharmaceutical and biomedical analysis

High-performance liquid chromatographic analysis of the investigational anticancer drug 9-aminocamptothecin, as the lactone form and as the total of the lactone and the hydroxycarboxylate forms, in micro-volumes of human plasma.

01-09-1998

Journal of chromatography. B, Biomedical sciences and applications

Determination of doxorubicin and metabolites in murine specimens by high-performance liquid chromatography.

07-08-1998

Anti-cancer drugs

O-glucuronidation, a newly identified metabolic pathway for topotecan and N-desmethyl topotecan.

01-08-1998

Journal of chromatography. B, Biomedical sciences and applications

Analysis of Ecteinascidin 743, a new potent marine-derived anticancer drug, in human plasma by high-performance liquid chromatography in combination with solid-phase extraction.

12-06-1998

Anti-cancer drugs

Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer.

01-06-1998

Pharmacological research

The pharmacological role of P-glycoprotein in the intestinal epithelium.

01-06-1998

Cancer research

Comparative pharmacology of the novel cyclopropylpyrroloindole-prodrug carzelesin in mice, rats, and humans.

01-06-1998

Journal of chromatography. B, Biomedical sciences and applications

Influence of Cremophor EL on the quantification of paclitaxel in plasma using high-performance liquid chromatography with solid-phase extraction as sample pretreatment.

08-05-1998

Cancer chemotherapy and pharmacology

A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I study.

02-04-1998

Annals of oncology : official journal of the European Society for Medical Oncology

Malignant effusions contain lysophosphatidic acid (LPA)-like activity.

01-04-1998

Cancer treatment reviews

Cisplatin resistance and DNA repair.

18-02-1998

European journal of cancer (Oxford, England : 1990)

Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines.

01-01-1998

Pharmacological research

Clinical research on antiangiogenic therapy.

01-01-1998

The Journal of clinical investigation

Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833.

15-11-1997

32P-postlabeling assay for the quantification of the major platinum-DNA adducts.

Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.

Compatibility and stability of aplidine, a novel marine-derived depsipeptide antitumor agent, in infusion devices, and its hemolytic and precipitation potential upon i.v. administration.

Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice.

Mice without phosphatidylcholine transfer protein have no defects in the secretion of phosphatidylcholine into bile or into lung airspaces.

[Hyperthermic intra-peritoneal chemotherapy (HIPEC) in patients with peritoneal pseudomyxoma or peritoneal metastases of colorectal carcinoma; good preliminary results from the Netherlands Cancer Institute].

Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients.

Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours.

Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC).

Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion.

Oral topotecan: bioavailablity and effect of food co-administration.

Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors.

Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.

Paclitaxel in the treatment of human immunodeficiency virus 1-associated Kaposi's sarcoma--drug-drug interactions with protease inhibitors and a nonnucleoside reverse transcriptase inhibitor: a case report study.

Quantification of topotecan and its metabolite N-desmethyltopotecan in human plasma, urine and faeces by high-performance liquid chromatographic methods.

Clinical pharmacology of anticancer agents in relation to formulations and administration routes.

Comparative pharmacokinetics of vinblastine after a 96-hour continuous infusion in wild-type mice and mice lacking mdr1a P-glycoprotein.

A single 24-hour plasma sample does not predict the carboplatin AUC from carboplatin-paclitaxel combinations or from a high-dose carboplatin-thiotepa-cyclophosphamide regimen.

Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.

Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer.

Potentiation of anti-cancer drug activity at low intratumoral pH induced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG).

Sampling technique from central venous catheters proves critical for pharmacokinetic studies.

Bioavailability and toxicity after oral administration of m-iodobenzylguanidine (MIBG).

Topoisomerase I/II inhibitor intoplicine administered as a 24 h infusion: phase I and pharmacologic study.

Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein.

Pharmaceutical development of a parenteral lyophilized formulation of the investigational antitumor neuropeptide antagonist [Arg6, D-Trp7,9, MePhe8]-Substance P [6-11].

High-performance liquid chromatographic bio-analysis of PSC 833 in human and murine plasma.

Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

Hepatitis during chloroguanide prophylaxis.

In-vitro metabolism of anti-cancer drugs, methods and applications: paclitaxel, docetaxel, tamoxifen and ifosfamide.

Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A.

High-performance liquid chromatographic determination of stabilized 4-hydroxyifosfamide in human plasma and erythrocytes.

Simultaneous determination of N,N',N"-triethylenethiophosphoramide, cyclophosphamide and some of their metabolites in plasma using capillary gas chromatography.

Multidrug resistance protein 1 protects the oropharyngeal mucosal layer and the testicular tubules against drug-induced damage.

Phase I and pharmacologic study of weekly doxorubicin and 1 h infusional paclitaxel in patients with advanced breast cancer.

Pharmacologic study of 3-hour 135 mg M-2 paclitaxel in platinum pretreated patients with advanced ovarian cancer.

High-performance liquid chromatographic analysis of the investigational anticancer drug 9-aminocamptothecin, as the lactone form and as the total of the lactone and the hydroxycarboxylate forms, in micro-volumes of human plasma.

Determination of doxorubicin and metabolites in murine specimens by high-performance liquid chromatography.

O-glucuronidation, a newly identified metabolic pathway for topotecan and N-desmethyl topotecan.

Analysis of Ecteinascidin 743, a new potent marine-derived anticancer drug, in human plasma by high-performance liquid chromatography in combination with solid-phase extraction.

Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer.

The pharmacological role of P-glycoprotein in the intestinal epithelium.

Comparative pharmacology of the novel cyclopropylpyrroloindole-prodrug carzelesin in mice, rats, and humans.

Influence of Cremophor EL on the quantification of paclitaxel in plasma using high-performance liquid chromatography with solid-phase extraction as sample pretreatment.

A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I study.

Malignant effusions contain lysophosphatidic acid (LPA)-like activity.

Cisplatin resistance and DNA repair.

Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines.

Clinical research on antiangiogenic therapy.

Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833.

This site uses cookies